Preventing Malaria by Vaccination

Fischer, Philip R..
December 2009
Travel Medicine Advisor;Dec2009, Vol. 19 Issue 12, p67
New formulations of malaria vaccines show increasing efficacy in protecting both children in malaria-endemic areas and malaria-naïve adults without previous malaria exposure.


Related Articles

  • Quarter-century quest for malaria vaccine shows signs of success. Opar, Alisa // Nature Reviews Drug Discovery;Dec2011, Vol. 10 Issue 12, p887 

    The article reports that GlaxoSmithKline (GSK) led ongoing trial of the vaccine candidate RTS,S, provides children with nearly 50% protection from severe bouts of the disease. The large-scale trial enrolled over 15,000 children aged either 6-12 weeks or 5-17 months in seven countries in...

  • Incorporating a quiz into informed consent processes: Qualitative study of participants' reactions. Molyneux, Sassy; Gikonyo, Caroline; Marsh, Vicki; Bejon, Philip // Malaria Journal;2007, Vol. 6, p145 

    Background: Formal checks of participant understanding are now widely recommended to improve informed consent processes. However, the views of the participants these assessments are designed to protect are rarely considered. In this paper the findings of a qualitative study aimed at documenting...

  • Pre-erythrocytic malaria vaccines: towards greater efficacy. Hill, Adrian V. S. // Nature Reviews Immunology;Jan2006, Vol. 6 Issue 1, p21 

    The complex life cycle of the malaria parasite Plasmodium falciparum provides many options for vaccine design. Several new types of vaccine are now being evaluated in clinical trials. Recently, two vaccine candidates that target the pre-erythrocytic stages of the malaria life cycle — a...

  • Malaria vaccine shows promise. Hampton, Tracy // JAMA: Journal of the American Medical Association;12/8/2004, Vol. 292 Issue 22, p2703 

    Reports on the development of a malaria vaccine and its effectiveness in children aged 1 to 4 in Africa. How the vaccine protects against uncomplicated malaria, infection and severe forms of the disease for at least 6 months; Details of a study of this vaccine; Amount of time that this vaccine...

  • Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12-24 Months-Old Burkinabe Children. Sirima, Sodiomon B.; Tiono, Alfred B.; Ouédraogo, Alphonse; Diarra, Amidou; Ouédraogo, André Lin; Yaro, Jean Baptiste; Ouédraogo, Espérance; Gansané, Adama; Bougouma, Edith C.; Konaté, Amadou T.; Kaboré, Youssouf; Traoré, Abdoulaye; Roma, Chilengi; Soulama, Issiaka; Luty, Adrian J. F.; Cousens, Simon; Nébié, Issa // PLoS ONE;2009, Vol. 4 Issue 10, p1 

    Background: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune...

  • Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial. Aide, Pedro; Aponte, John J.; Renom, Montse; Nhampossa, Tacilta; Sacarlal, Jahit; Mandomando, Inacio; Bassat, Quique; Manaca, Maria Nélia; Leach, Amanda; Lievens, Marc; Vekemans, Johan; Dubois, Marie-Claude; Loucq, Christian; Ballou, W. Ripley; Cohen, Joe; Alonso, Pedro L. // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: The RTS,S/AS02D vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants. Methods and Findings: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02D given at 10, 14 and 18 weeks of age...

  • Status of malaria vaccine research. Targett, G. A. T. // Journal of the Royal Society of Medicine (Supplement);Jul1989, Vol. 82 Issue 17, p52 

    The article focuses on the status of research on malaria vaccine. It cites the factors that hinder the development of vaccines that will be added to the existing but progressively less effective methods of control of malaria. It mentions the importance of T cells in immunity to malaria. Recent...

  • Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. Sedegah, Martha; Tamminga, Cindy; McGrath, Shannon; House, Brent; Ganeshan, Harini; Lejano, Jennylynn; Abot, Esteban; Banania, Glenna J.; Sayo, Renato; Farooq, Fouzia; Belmonte, Maria; Manohar, Nalini; Richie, Nancy O.; Wood, Chloe; Long, Carole A.; Regis, David; Williams, Francis T.; Meng Shi; Ilin Chuang; Spring, Michele // PLoS ONE;2011, Vol. 6 Issue 10, p1 

    Background: Models of immunity to malaria indicate the importance of CD8+ T cell responses for targeting intrahepatic stages and antibodies for targeting sporozoite and blood stages. We designed a multistage adenovirus 5 (Ad5)-vectored Plasmodium falciparum malaria vaccine, aiming to induce both...

  • Malaria Vaccine.  // Time International (South Pacific Edition);10/25/2004, Issue 42, p85 

    The article reports that a malaria vaccine, being tested in Africa, has been found to protect children from the disease 30% of the time. The vaccine also lessens the severity of illness in nearly 60%of cases. The vaccine is not ready for use yet, even if the world can ill afford to wait.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics